A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Pancreatic Cancer
DRUG: ABI-007
Overall Survival, Number of participants who survive, up to 3 years
Disease progression, Date of disease progression and subsequent anticancer therapy for pancreatic adenocarcinoma other than that already recorded for subject while enrolled in CA046, up to 3 years
A study to collect survival status of CA046 subjects who were know to be alive at the last report of vital status for CA046 - approximate timeframe - end of March, 2013. Once consent is given, on a quarterly basis, information on status will be collected to include:

* Vital Status
* Date of disease progression
* Subsequent anticancer therapy for pancreatic adenocarcinoma